Anti-EMMPRIN Monoclonal Antibody as a Novel Agent for Therapy of Head and Neck Cancer
- 15 June 2009
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (12) , 4058-4065
Abstract
Purpose: Extracellular matrix metalloprotease inducer (EMMPRIN) is a tumor surface protein that promotes growth and is overexpressed in head and neck cancer. These features make it a potential therapeutic target for monoclonal antibody (mAb)–based therapy. Because molecular therapy is considered more effective when delivered with conventional cytotoxic agents, anti-EMMPRIN therapy was assessed alone and in combination with external beam radiation. Experimental Design: Using a murine flank model, loss of EMMPRIN function was achieved by transfection with a small interfering RNA against EMMPRIN or treatment with a chimeric anti-EMMPRIN blocking mAb. Cytokine expression was assessed for xenografts, tumor cells, fibroblasts, and endothelial cells. Results: Animals treated with anti-EMMPRIN mAb had delayed tumor growth compared with untreated controls, whereas treatment with combination radiation and anti-EMMPRIN mAb showed the greatest reduction in tumor growth (P = 0.001). Radiation-treated EMMPRIN knockdown xenografts showed a reduction in tumor growth compared with untreated knockdown controls (P = 0.01), whereas radiation-treated EMMPRIN–expressing xenografts did not show a delay in tumor growth. Immunohistochemical evaluation for Ki67 and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL) resulted in a reduction in proliferation (P = 0.007) and increased apoptosis in anti-EMMPRIN mAb–treated xenografts compared with untreated controls (P = 0.087). In addition, we provide evidence that EMMPRIN suppression results in decreased interleukin 1β (IL-1β), IL-6, and IL-8 cytokine production, in vitro and in vivo. Conclusions: These data suggest that anti-EMMPRIN antibody inhibits tumor cell proliferation in vivo and may represent a novel targeted treatment option in head and neck squamous cell carcinoma.Keywords
This publication has 34 references indexed in Scilit:
- Evolution of clinical trials in head and neck cancerCritical Reviews in Oncology/Hematology, 2009
- Modulation of Tumor Cell Growth In Vivo by Extracellular Matrix Metalloprotease InducerJAMA Otolaryngology–Head & Neck Surgery, 2008
- In vivo Efficacy of Marimastat and Chemoradiation in Head and Neck Cancer XenograftsORL, 2008
- EMMPRIN Expression as a Prognostic Factor in Radiotherapy of Cervical CancerClinical Cancer Research, 2008
- Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivoClinical Cancer Research, 2007
- Extracellular Matrix Metalloprotease Inducer Stimulates Fibroblast-Mediated Tumor Growth In VivoThe Laryngoscope, 2006
- A Protective Role for Matrix Metalloproteinase-3 in Squamous Cell CarcinomaCancer Research, 2004
- Expression of Extracellular Matrix Metalloprotease Inducer in Laryngeal Squamous Cell CarcinomaThe Laryngoscope, 2003
- Heterotypic Signaling between Epithelial Tumor Cells and Fibroblasts in Carcinoma FormationExperimental Cell Research, 2001
- Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and RadiationCancer Biotherapy and Radiopharmaceuticals, 1999